Biopharmaceutical Industry Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Report Covers Global Biopharmaceuticals Market Size, Segmentation & Growth and is Segmented by Product Type (Monoclonal Antibodies, Recombinant Growth Factors, Purified Proteins, Recombinant Proteins, Recombinant Hormones, Vaccines, Recombinant Enzymes, Cell, Gene Therapies, Cytokines, Interferons, and Interleukins, and Other Product Types), Therapeutic Application (Oncology, Inflammatory and Infectious Diseases, Autoimmune Disorders, Metabolic Disorders, Hormonal Disorders, Cardiovascular Diseases, Neurological Diseases, and Other Diseases), and Geography (North America, Europe, Asia-Pacific, Middle East, and Africa, and South America). The Report Offers the Value in (USD) for the Above Segments.

Biopharmaceutical Industry Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Biopharmaceuticals Market Size

Biopharmaceuticals Market Summary
Study Period 2019 - 2030
Market Size (2025) USD 431.81 Billion
Market Size (2030) USD 621.65 Billion
CAGR (2025 - 2030) 7.56 %
Fastest Growing Market Asia Pacific
Largest Market North America
Market Concentration High

Major Players

Biopharmaceuticals Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of Biopharmaceuticals Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

Biopharmaceuticals Market Analysis

The Biopharmaceuticals Market size is estimated at USD 431.81 billion in 2025, and is expected to reach USD 621.65 billion by 2030, at a CAGR of 7.56% during the forecast period (2025-2030).

The COVID-19 pandemic had a significant impact on the Biopharmaceutical industry. Thus, Biopharma Industry Trends shifted to most Biopharmaceutical companies striving extensively to develop vaccines against the SARS-CoV-2 virus. For instance, in June 2022, Pfizer announced a USD 120 million investment for its Kalamazoo (Michigan) facility, enabling United States-based production for its COVID-19 oral treatment, PAXLOVID (nirmatrelvir tablets and ritonavir tablets). The increased interest in manufacturing COVID-19 vaccines significantly added to the growth of the Biopharmaceutical industry during the COVID-19 pandemic. Following the stabilization from COVID-19, the increasing prevalence of chronic diseases is expected to further shift the Biopharma Industry Trends toward developing solutions for chronic diseases, driving the growth of the Biopharmaceutical industry.

Factors like rising chronic disease prevalence and increasing acceptance and demand for Biopharmaceuticals owing to their ability to treat previously untreatable diseases are driving the market's growth. For instance, in September 2022, a report by the WHO stated that about 55 million people worldwide are living with dementia, and nearly 10 million cases are reported annually. The WHO also highlighted that Alzheimer's is the most common form of dementia and constitutes about 60-70% of the total cases of dementia. As per the same source, most people who develop Alzheimer's dementia are 65 years and above. Such a high disease prevalence is likely to facilitate the demand for effective treatment, which in turn will bolster Biopharma Market Growth over the coming years.

The Biopharmaceutical Products' ability to address previously untreatable conditions has paved the way for introducing innovative drugs in the market. For instance, in September 2022, the Center for Biologics Evaluation and Research (CBER) approved Bluebird Bio, Inc.'s SKYSONA (elivaldogene autotemcel), a Gene Therapy indicated to slow the progression of neurologic dysfunction in boys 4-17 years of age with early, active cerebral adrenoleukodystrophy (CALD). Similarly, in June 2022, CBER approved GlaxoSmithKline's PRIORIX, a live vaccine for measles, mumps, and rubella. Thus, such product approvals increase the availability of novel drugs in the market, which is expected to boost the Biopharmaceutical Industry Growth over the forecast period.

Furthermore, in February 2022, Johnson & Johnson, one of the Largest Biopharmaceutical Companies, and its China-focused partner company Legend Biotech Corp. developed a therapy to treat a type of white blood cell cancer approved by the United States Food and Drug Administration (FDA). Thus, the development of new therapies that aid in treating oncologic disorders is anticipated to have a positive impact on the growth of the Biopharmaceutical industry over the forecast period.

Thus, factors such as rising chronic disease prevalence, product launches, and approvals over the forecast period are likely to facilitate market growth over the forecast period. However, high-end manufacturing and complicated and cumbersome regulatory requirements will hinder Biopharmaceuticals Market Growth over the forecast period.

Biopharmaceuticals Industry Overview

The Biopharmaceutical Industry is fragmented in nature due to the presence of several companies operating globally. The competitive landscape includes analyzing a few well-known international and local companies, including some of the Largest Biopharmaceutical Companies that hold market shares. Furthermore, companies adopt various strategic measures such as acquisitions, partnerships, collaborations, and new product launches to expand in the market and enhance their Biopharmaceutical Marketing strategies. Some of the Largest Biopharmaceutical Companies in the industry include Amgen Inc., Eli Lilly and Company, Johnson and Johnson, Abbvie Inc., and Bristol-Myers Squibb Company, among others.

Biopharmaceuticals Market Leaders

  1. Amgen Inc.

  2. Abbvie Inc.

  3. Bristol-Myers Squibb Company

  4. Eli Lilly and Company

  5. Johnson & Johnson​

  6. *Disclaimer: Major Players sorted in no particular order
Biopharmaceuticals Market Concentration
Need More Details on Market Players and Competiters?
Download PDF

Biopharmaceuticals Market News

  • July 2023: Pfizer invested USD 25 million in Caribou Biosciences to progress an immune-cloaked allogeneic CAR-T cell therapy, CB-011. The company is currently evaluating the cell therapy in a Phase I CaMMouflage clinical trial for relapsed or refractory multiple myeloma.
  • April 2023: InflaRx N.V.'s Gohibic (vilobelimab), a first-in-class monoclonal anti-human complement factor C5a antibody, was granted an Emergency Use Authorization by the United States Food and Drug Administration for the treatment of COVID-19 in hospitalized adults when initiated within 48 hours of receiving invasive mechanical ventilation, or extracorporeal membrane oxygenation.

Biopharmaceutical Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Acceptance of and Huge Market Demand for Biopharmaceuticals
    • 4.2.2 Ability of Biopharmaceuticals to Treat Previously Untreatable Diseases
  • 4.3 Market Restraints
    • 4.3.1 High-end Manufacturing Requirements
    • 4.3.2 Complicated and Cumbersome Regulatory Requirements
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Bargaining Power of Suppliers
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Threat of New Entrants
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION

  • 5.1 By Product Type
    • 5.1.1 Monoclonal Antibodies
    • 5.1.1.1 Anti-cancer Monoclonal Antibodies
    • 5.1.1.2 Anti-inflammatory Monoclonal Antibodies
    • 5.1.1.3 Other Monoclonal Antibodies
    • 5.1.2 Recombinant Growth Factors
    • 5.1.2.1 Erythropoietin
    • 5.1.2.2 Granulocyte Colony Stimulating Factor
    • 5.1.3 Purified Proteins
    • 5.1.3.1 Leukemia Inhibitory Factor (LIF)
    • 5.1.3.2 P53 Protein
    • 5.1.3.3 P38 Protein
    • 5.1.3.4 Other Purified Proteins
    • 5.1.4 Recombinant Proteins
    • 5.1.4.1 Serum Albumin
    • 5.1.4.2 Amyloid Protein
    • 5.1.4.3 Defensin
    • 5.1.4.4 Transferrin
    • 5.1.5 Recombinant Hormones
    • 5.1.5.1 Recombinant Human Growth Hormones
    • 5.1.5.2 Recombinant Insulin
    • 5.1.5.3 Other Recombinant Hormones
    • 5.1.6 Vaccines
    • 5.1.6.1 Recombinant Vaccines
    • 5.1.6.1.1 Cancer Vaccine
    • 5.1.6.1.2 Malaria Vaccine
    • 5.1.6.1.3 Ebola Vaccine
    • 5.1.6.1.4 Hepatitis-B Vaccine
    • 5.1.6.1.5 Tetanus Vaccine
    • 5.1.6.1.6 Diptheria Vaccine
    • 5.1.6.1.7 Cholera Vaccine
    • 5.1.6.1.8 Other Recombinant Vaccines
    • 5.1.6.2 Conventional Vaccines
    • 5.1.6.2.1 Polio Vaccine
    • 5.1.6.2.2 Pox Vaccine
    • 5.1.6.2.3 Other Conventional Vaccines
    • 5.1.7 Recombinant Enzymes
    • 5.1.7.1 Enterokinase
    • 5.1.7.2 Cyclase
    • 5.1.7.3 Caspase
    • 5.1.7.4 Cathepsin
    • 5.1.8 Cell and Gene Therapies
    • 5.1.8.1 Allogenic Products
    • 5.1.8.2 Autologous Products
    • 5.1.8.3 Acellular Products
    • 5.1.9 Cytokines, Interferons, and Interleukins
    • 5.1.10 Other Product Types
    • 5.1.10.1 Blood Factors
    • 5.1.10.2 Other Product Types
  • 5.2 By Therapeutic Application
    • 5.2.1 Oncology
    • 5.2.2 Inflammatory and Infectious Diseases
    • 5.2.3 Autoimmune Disorders
    • 5.2.4 Metabolic Disorders
    • 5.2.5 Hormonal Disorders
    • 5.2.6 Cardiovascular Diseases
    • 5.2.7 Neurological Diseases
    • 5.2.8 Other Therapeutic Applications
  • 5.3 Geography
    • 5.3.1 North America
    • 5.3.1.1 United States
    • 5.3.1.2 Canada
    • 5.3.1.3 Mexico
    • 5.3.2 Europe
    • 5.3.2.1 Germany
    • 5.3.2.2 United Kingdom
    • 5.3.2.3 France
    • 5.3.2.4 Italy
    • 5.3.2.5 Spain
    • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
    • 5.3.3.1 China
    • 5.3.3.2 Japan
    • 5.3.3.3 India
    • 5.3.3.4 Australia
    • 5.3.3.5 South Korea
    • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
    • 5.3.4.1 GCC
    • 5.3.4.2 South Africa
    • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
    • 5.3.5.1 Brazil
    • 5.3.5.2 Argentina
    • 5.3.5.3 Rest of South America

6. COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Abbvie Inc.
    • 6.1.2 Amgen Inc.
    • 6.1.3 Bristol-Myers Squibb Company
    • 6.1.4 Eli Lilly and Company
    • 6.1.5 Johnson & Johnson
    • 6.1.6 Novartis AG
    • 6.1.7 Novo Nordisk AS
    • 6.1.8 Pfizer Inc.
    • 6.1.9 GlaxoSmithKline PLC
    • 6.1.10 F. Hoffmann-La Roche AG
    • 6.1.11 Merck Co. & Inc.
    • 6.1.12 Sanofi SA
    • 6.1.13 AstraZeneca PLC
    • 6.1.14 Bayer AG
    • 6.1.15 Takeda Pharmaceutical Company Limited
  • *List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers Business Overview, Financials, Products and Strategies, and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Biopharmaceuticals Industry Segmentation

As per the scope of the report, biopharmaceuticals refer to any biologically synthesized molecules used to treat or manage disorders. These are derived by recombinant DNA technology and produced in bacterial, yeast, insect, plant, or mammalian cell expression systems, hybridomas, or primary or continuous cell lines.

The biopharmaceutical industry is segmented by product type (Monoclonal Antibodies (Anti-cancer Monoclonal Antibodies, Anti-inflammatory Monoclonal Antibodies, Other Monoclonal Antibodies), Recombinant Growth Factors (Erythropoietin, Granulocyte Colony Stimulating Factor), Purified Proteins (Leukemia Inhibitory Factor (LIF), P53 Protein, P38 Protein, Other Purified Proteins), Recombinant Proteins (Serum Albumin, Amy loid Protein, Defensin, Transferrin), Recombinant Hormones (Recombinant Human Growth Hormones, Recombinant Insulin, Other Recombinant Hormones), Vaccines (Recombinant Vaccines (Cancer Vaccine, Malaria Vaccine, Ebola Vaccine, Hepatitis-B Vaccine, Tetanus Vaccine, Diptheria Vaccine, Cholera Vaccine, Other Recombinant Vaccines), Conventional Vaccines (Polio Vaccine, Pox Vaccine, Other Conventional Vaccines)), Recombinant Enzymes (Enterokinase, Cyclase, Caspase, Cathepsin), Cell And Gene Therapies (Allogenic Products, Autologous Products, Acellular Products), Cytokines, Interferons, and Interleukins, and Other Product Types), Therapeutic Application (Oncology, Inflammatory and infectious Diseases, Autoimmune Disorders, Metabolic Disorders, Hormonal Disorders, cardiovascular Diseases, Neurological Diseases, and Other Therapeutic Applications), and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report also covers the biopharmaceuticals market sizes and trends for 17 countries across major regions globally.

The report offers the value in (USD) for the above-mentioned segments.

By Product Type Monoclonal Antibodies Anti-cancer Monoclonal Antibodies
Anti-inflammatory Monoclonal Antibodies
Other Monoclonal Antibodies
Recombinant Growth Factors Erythropoietin
Granulocyte Colony Stimulating Factor
Purified Proteins Leukemia Inhibitory Factor (LIF)
P53 Protein
P38 Protein
Other Purified Proteins
Recombinant Proteins Serum Albumin
Amyloid Protein
Defensin
Transferrin
Recombinant Hormones Recombinant Human Growth Hormones
Recombinant Insulin
Other Recombinant Hormones
Vaccines Recombinant Vaccines Cancer Vaccine
Malaria Vaccine
Ebola Vaccine
Hepatitis-B Vaccine
Tetanus Vaccine
Diptheria Vaccine
Cholera Vaccine
Other Recombinant Vaccines
Conventional Vaccines Polio Vaccine
Pox Vaccine
Other Conventional Vaccines
Recombinant Enzymes Enterokinase
Cyclase
Caspase
Cathepsin
Cell and Gene Therapies Allogenic Products
Autologous Products
Acellular Products
Cytokines, Interferons, and Interleukins
Other Product Types Blood Factors
Other Product Types
By Therapeutic Application Oncology
Inflammatory and Infectious Diseases
Autoimmune Disorders
Metabolic Disorders
Hormonal Disorders
Cardiovascular Diseases
Neurological Diseases
Other Therapeutic Applications
Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Biopharmaceutical Market Research FAQs

How big is the Biopharmaceuticals Market?

The Biopharmaceuticals Market size is expected to reach USD 431.81 billion in 2025 and grow at a CAGR of 7.56% to reach USD 621.65 billion by 2030.

What is the current Biopharmaceuticals Market size?

In 2025, the Biopharmaceuticals Market size is expected to reach USD 431.81 billion.

Who are the key players in Biopharmaceuticals Market?

Amgen Inc., Abbvie Inc., Bristol-Myers Squibb Company, Eli Lilly and Company and Johnson & Johnson​ are the major companies operating in the Biopharmaceuticals Market.

Which is the fastest growing region in Biopharmaceuticals Market?

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).

Which region has the biggest share in Biopharmaceuticals Market?

In 2025, the North America accounts for the largest market share in Biopharmaceuticals Market.

What years does this Biopharmaceuticals Market cover, and what was the market size in 2024?

In 2024, the Biopharmaceuticals Market size was estimated at USD 399.17 billion. The report covers the Biopharmaceuticals Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Biopharmaceuticals Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

Biopharma Industry Report

The global biopharmaceutical market is experiencing significant market growth, driven by the increasing demand for personalized medicines and advancements in biotechnology. These biologics, produced from biological sources through biotechnological processes, are transforming the treatment of previously challenging diseases due to their high specificity and reduced side effects. The market size is expanding as these treatments precisely target specific receptors or molecules, making them highly effective for conditions such as cancer, diabetes, and autoimmune diseases.

The market segmentation includes various product types like monoclonal antibodies, recombinant growth factors, purified proteins, recombinant proteins, recombinant hormones, vaccines, recombinant enzymes, cell and gene therapies, cytokines, interferons, and interleukins. Therapeutic applications cover oncology, inflammatory and infectious diseases, autoimmune disorders, metabolic disorders, hormonal disorders, cardiovascular diseases, neurological diseases, and other diseases. This comprehensive market overview highlights the industry's potential for significant growth.

The industry trends indicate a growing focus on rare diseases and orphan drugs, with incentives and streamlined regulatory processes encouraging the development of these therapies. Leading segments such as autoimmune diseases and monoclonal antibodies underscore their effectiveness in managing complex conditions. Additionally, the market leaders are investing in research companies and expanding their R&D efforts to introduce novel products, aiming to address the escalating global healthcare needs.

The industry analysis provided by Mordor Intelligence™ offers a detailed market forecast and historical overview, emphasizing the sector's growth rate. The market value is further bolstered by the increasing demand for vaccines and strategic expansion of R&D. This market report serves as a valuable resource for understanding the industry's outlook and trends, providing essential industry information and statistics.

For those interested in a deeper dive into the market data, a report example and report pdf are available for download. These industry reports and industry research documents offer insights into the market's segmentation, industry size, and sales. The market predictions and market review reflect the dynamic nature of the biopharmaceutical sector, making it crucial for stakeholders to stay informed about the latest developments and market outlook.